Vivo Innovation holds 5.5% of BlossomHill

BlossomHill Therapeutics, Inc. (BLSM) reports that Vivo Innovation Fund II Holdings, L.P., together with its general partner Vivo Innovation II, LLC, has filed a Schedule 13G disclosing beneficial ownership of the company’s common stock.

Rhea-AI Filing Summary

BlossomHill Therapeutics, Inc. (BLSM) reports that Vivo Innovation Fund II Holdings, L.P., together with its general partner Vivo Innovation II, LLC, has filed a Schedule 13G disclosing beneficial ownership of the company’s common stock.

The filing states that Vivo Innovation Fund II Holdings, L.P. beneficially owns 1,681,240 shares of BlossomHill Therapeutics common stock, representing 5.5% of the outstanding class. The reporting persons have sole voting and sole dispositive power over these shares, with no shared voting or dispositive power. The ownership percentage is based on 30,643,660 shares outstanding after completion of BlossomHill Therapeutics’ initial public offering, as described in the company’s prospectus filed with the SEC on August 7, 2026.

Key Figures

Shares beneficially owned: 1,681,240 shares Ownership percentage: 5.5% Shares outstanding baseline: 30,643,660 shares +3 more

6 metrics

Shares beneficially owned 1,681,240 shares Common stock of BlossomHill Therapeutics held of record by Vivo Innovation Fund II Holdings, L.P.

Ownership percentage 5.5% Percent of BlossomHill Therapeutics common stock class beneficially owned by each reporting person

Shares outstanding baseline 30,643,660 shares BlossomHill Therapeutics common stock outstanding after the IPO, excluding full over-allotment exercise

Sole voting power 1,681,240 shares Shares over which the reporting persons have sole power to vote or direct the vote

Sole dispositive power 1,681,240 shares Shares over which the reporting persons have sole power to dispose or direct the disposition

Prospectus date August 7, 2026 Date of the prospectus used to determine shares outstanding for the ownership calculation

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Schedule 13G, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 1,681,240 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 1,681,240.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"7 | Sole Dispositive Power 1,681,240.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

""form_type": "SCHEDULE 13G""

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

underwriters' over-allotment option financial

"shares outstanding (excluding the full exercise of the underwriters' over-allotment option)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of BlossomHill Therapeutics (BLSM) does Vivo Innovation Fund II Holdings, L.P. own?

Vivo Innovation Fund II Holdings, L.P. beneficially owns 1,681,240 shares of BlossomHill Therapeutics common stock, representing 5.5% of the outstanding class. This stake is calculated using 30,643,660 shares outstanding after the company’s initial public offering.

What percentage of BlossomHill Therapeutics (BLSM) is controlled by the Vivo Innovation entities?

The filing reports that both Vivo Innovation Fund II Holdings, L.P. and Vivo Innovation II, LLC each have beneficial ownership of 5.5% of BlossomHill Therapeutics’ common stock. This is based on 30,643,660 shares of common stock outstanding after the IPO.

Does Vivo Innovation Fund II Holdings, L.P. have sole or shared voting power in BLSM?

The reporting persons have sole voting power over 1,681,240 shares of BlossomHill Therapeutics common stock and no shared voting power. They also report sole dispositive power over the same number of shares, indicating exclusive authority over how these shares are voted and disposed.

What is the total number of BlossomHill Therapeutics (BLSM) shares outstanding used in this Schedule 13G?

The ownership percentage is calculated using 30,643,660 shares of BlossomHill Therapeutics common stock outstanding. This figure reflects shares outstanding after completion of the initial public offering, excluding full exercise of the underwriters’ over-allotment option, as described in the company’s August 7, 2026 prospectus.

Who filed the Schedule 13G for BlossomHill Therapeutics (BLSM) and what are their roles?

The Schedule 13G is filed by Vivo Innovation Fund II Holdings, L.P. and its general partner Vivo Innovation II, LLC. Vivo Innovation Fund II Holdings, L.P. holds the 1,681,240 shares of BlossomHill Therapeutics common stock of record, and Vivo Innovation II, LLC acts as the general partner.

Is the 5.5% BLSM ownership tied to the recent IPO terms?

Yes. The reported 5.5% ownership by the Vivo Innovation entities is based on 30,643,660 shares of common stock outstanding after BlossomHill Therapeutics’ initial public offering, as reported in the company’s prospectus filed with the SEC on August 7, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 03:55 PM Accepted by SEC EDGAR 08/17/2026 - 03:46 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BlossomHill Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

095130100

(CUSIP Number)

08/10/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 095130100

1

Names of Reporting Persons

Vivo Innovation Fund II Holdings, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,681,240.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,681,240.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,681,240.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The number represents shares of common stock, par value $0.0001 per share (the "Common Stock") of BlossomHill Therapeutics, Inc. (the "Issuer"), which are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P. The percent is based on 30,643,660 shares of the Issuer's Common Stock outstanding (excluding the full exercise of the underwriters' over-allotment option) after the completion of the initial public offering, as reported in the Issuer's prospectus filed with the Securities and Exchange Commission (the "SEC") on August 7, 2026, pursuant to Rule 424(b)(4), which forms part of the Issuer's Registration Statement on Form S-1 (File No. 333-297512).

SCHEDULE 13G

CUSIP Number(s): 095130100

1

Names of Reporting Persons

Vivo Innovation II, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,681,240.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,681,240.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,681,240.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer, which are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P. The percent is based on 30,643,660 shares of the Issuer's Common Stock outstanding (excluding the full exercise of the underwriters' over-allotment option) after the completion of the initial public offering, as reported in the Issuer's prospectus filed with the SEC on August 7, 2026, pursuant to Rule 424(b)(4), which forms part of the Issuer's Registration Statement on Form S-1 (File No. 333-297512).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BlossomHill Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 10255 Science Center Drive, Suite 200, San Diego, California 92121
Item 2.
(a)	Name of person filing: Vivo Innovation Fund II Holdings, L.P. and its General Partner Vivo Innovation II, LLC
(b)	Address or principal business office or, if none, residence: 192 Lytton Avenue, Palo Alto, CA 94301
(c)	Citizenship: Vivo Innovation Fund II Holdings, L.P. is a Delaware limited partnership. Vivo Innovation II, LLC is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 095130100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,681,240 shares of the Issuer's Common Stock are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P.
(b)	Percent of class: Vivo Innovation Fund II Holdings, L.P.: 5.5% Vivo Innovation II, LLC: 5.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Vivo Innovation Fund II Holdings, L.P.: 1,681,240 shares Vivo Innovation II, LLC: 1,681,240 shares
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: Vivo Innovation Fund II Holdings, L.P.: 1,681,240 shares Vivo Innovation II, LLC: 1,681,240 shares
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vivo Innovation Fund II Holdings, L.P.

Signature:	/s/ Gaurav Aggarwal
Name/Title:	Gaurav Aggarwal/Managing Member of Vivo Innovation II, LLC, General Partner
Date:	08/17/2026

Vivo Innovation II, LLC

Signature:	/s/ Gaurav Aggarwal
Name/Title:	Gaurav Aggarwal/Managing Member
Date:	08/17/2026

Exhibit Information

99.1 Joint Filing Statement